Ionis Pharmaceuticals, Inc. (LON:0JDI)

Market Cap	4.06B
Revenue (ttm)	563.24M
Net Income (ttm)	-362.56M
Shares Out	n/a
EPS (ttm)	-2.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	271
Average Volume	749
Open	32.42
Previous Close	32.67
Day's Range	32.39 - 32.74
52-Week Range	31.94 - 53.95
Beta	n/a
RSI	48.88
Earnings Date	Feb 19, 2025

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 927
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDI

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Financial numbers in USD